Aducanumab

Summary

Aducanumab (CHEMBL3039540) is an approved antibody (ATC N06DX03); indicated across 2 conditions including dementia and alzheimer disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: N06DX03
• Indications: 2 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3039540
Name	Aducanumab
Type	Antibody
Max phase	4
ATC	N06DX03

Also known as: Aducanumab, Aducanumab avwa, Aducanumab-avwa, Aduhelm, BIIB-037, BIIB037, ADUCANUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
dementia	4	MONDO:0001627	HP:0000726
Alzheimer disease	4	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE3	5
PHASE1	5
PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02477800	PHASE3	TERMINATED	221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease
NCT02484547	PHASE3	TERMINATED	221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease
NCT04241068	PHASE3	TERMINATED	A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
NCT05108922	PHASE3	COMPLETED	A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 4)
NCT05310071	PHASE3	TERMINATED	A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer’s Disease
NCT03639987	PHASE2	TERMINATED	A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer’s Disease or With Mild Alzheimer’s Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
NCT01397539	PHASE1	COMPLETED	Single Ascending Dose Study of BIIB037 in Participants With Alzheimer’s Disease
NCT02434718	PHASE1	COMPLETED	Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer’s Disease
NCT02782975	PHASE1	COMPLETED	Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
NCT04924140	PHASE1	COMPLETED	A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers
NCT05216887	PHASE1	COMPLETED	A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers
NCT05469009	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer’s Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).